Literature DB >> 28117008

A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?

Wala Ben Kridis1, Nabil Toumi, Hadil Chaari, Afef Khanfir, Kamel Ayadi, Hassib Keskes, Tahia Boudawara, Jamel Daoud, Mounir Frikha.   

Abstract

BACKGROUND: The Ewing sarcoma (ES) represents 10 to 15% malignant bone tumors and 40 to 45% pediatric malignant bone tumors. The aim of this review is to clarify the therapeutic results and prognostic factors of this entity.
METHODS: A systematic review of the literature was performed. Studies focused on the management of ES were considered for inclusion. RESULT: ES represents a model of multidisciplinary approach. The optimization of ES multimodality therapeutic strategies has resulted from the efforts of several national and international groups in Europe and North America and from cooperation between the pediatric and medical oncologists. The overall 5- year survival of Ewing localized tumors was 70% versus 30% in metastatic ES.
CONCLUSION: The treatment of ES includes neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy for control of the primary site and possible metastatic disease. The role of high-dose chemotherapy is still debated. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Chemotherapy; ewing sarcoma; malignant bone tumors; prognostic factor; therapeutic strategies; treatment

Mesh：

Year:  2017        PMID： 28117008     DOI： 10.2174/1574887112666170120100147

Source DB:  PubMed          Journal:  Rev Recent Clin Trials        ISSN： 1574-8871


  10 in total

Review 1.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

2.  Fatal course of undetected Ewing-like sarcoma in a 9-year-old boy with uncharacteristic clinical presentation.

Authors:  Walther Gotsmy; Bettina Neumayer; Theo Kraus; Barbara Zellinger; Daniel Neureiter; Fabio Monticelli; Harald Meyer; Peter Hofer
Journal:  Forensic Sci Med Pathol       Date:  2021-11-15       Impact factor: 2.456

3.  [Severe respiratory insufficiency as manifestation of a pulmonary metastasized Ewing's sarcoma].

Authors:  M Schöffner; J Fichte; A Starl; S Ullrich; H-B Hopf
Journal:  Anaesthesist       Date:  2020-09-23       Impact factor: 1.041

4.  Survival and Scoliosis Following Resection of Chest Wall Tumors in Children and Adolescents: A Single-center Retrospective Analysis.

Authors:  James A Saltsman; Enrico Danzer; William J Hammond; Daniel Rhee; Simon Berhe; Julie Monteagudo; Anita P Price; Todd E Heaton; David R Jones; Michael P LaQuaglia
Journal:  Ann Surg       Date:  2021-08-01       Impact factor: 13.787

Review 5.  On the Cutting Edge: Regulation and Therapeutic Potential of the mRNA 3' End Nuclease.

Authors:  Huiyun Liu; Claire L Moore
Journal:  Trends Biochem Sci       Date:  2021-04-30       Impact factor: 14.264

Review 6.  Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development.

Authors:  Daniel Y Lee; Arthur P Staddon; Jacob E Shabason; Ronnie Sebro
Journal:  Cancer Med       Date:  2019-01-10       Impact factor: 4.452

7.  High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma.

Authors:  Martin F Orth; Tilman L B Hölting; Marlene Dallmayer; Fabienne S Wehweck; Tanja Paul; Julian Musa; Michaela C Baldauf; Didier Surdez; Olivier Delattre; Maximilian M L Knott; Laura Romero-Pérez; Merve Kasan; Florencia Cidre-Aranaz; Julia S Gerke; Shunya Ohmura; Jing Li; Aruna Marchetto; Anton G Henssen; Özlem Özen; Shintaro Sugita; Tadashi Hasegawa; Takayuki Kanaseki; Stefanie Bertram; Uta Dirksen; Wolfgang Hartmann; Thomas Kirchner; Thomas G P Grünewald
Journal:  Cancers (Basel)       Date:  2020-03-10       Impact factor: 6.639

Review 8.  Cervical intramedullary recurrent Ewing sarcoma after 10-year disease-free survival in an adult: a case report and review of literature.

Authors:  Keita Fukushima; Osahiko Tsuji; Satoshi Suzuki; Satoshi Nori; Narihito Nagoshi; Eijiro Okada; Mitsuru Yagi; Katsura Emoto; Robert Nakayama; Kota Watanabe; Masaya Nakamura; Morio Matsumoto
Journal:  Spinal Cord Ser Cases       Date:  2021-05-27

9.  IRE1α-XBP1 inhibitors exerted anti-tumor activities in Ewing's sarcoma.

Authors:  Yu Tanabe; Yoshiyuki Suehara; Shinji Kohsaka; Takuo Hayashi; Keisuke Akaike; Kenta Mukaihara; Taisei Kurihara; Youngji Kim; Taketo Okubo; Midori Ishii; Saiko Kazuno; Kazuo Kaneko; Tsuyoshi Saito
Journal:  Oncotarget       Date:  2018-02-12

10.  Outcome of multidisciplinary treatment of peripheral primitive neuroectodermal tumor.

Authors:  Yidi Liu; Yan Yuan; Fuquan Zhang; Ke Hu; Jie Qiu; Xiaorong Hou; Junfang Yan; Xin Lian; Shuai Sun; Zhikai Liu; Jie Shen
Journal:  Sci Rep       Date:  2020-09-24       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.